Therefore, even in the absence of extended clinical follow-up data, we have identified what we believe are previously unappreciated features of prostate tumor cells with direct clinical significance in their sensitivity to HER2 inhibition while demonstrating resistance to enzalutamide. This evidence concerns the gene ERBB2 and prostate neoplasm.